Physician profile
Jayna Ling
NPI 1538616214
$2,254.34
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $390 · 2022: $1,097 · 2023: $767.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $767.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,174.73 | 2021-2023 | Gallant, Amplatzer Amulet, Aveir |
| Impulse Dynamics (USA) INC. | $282.55 | 2022-2023 | Optimizer |
| Medtronic, INC. | $272.14 | 2022 | |
| Merck Sharp & Dohme LLC | $118.09 | 2021-2023 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $86.23 | 2021-2023 | Lifevest |
| Boston Scientific Corporation | $64.59 | 2022 | |
| Novartis Pharmaceuticals Corporation | $60.40 | 2022-2023 | |
| Zoll Respicardia, INC. | $45.41 | 2023 | Remede System |
| Altathera Pharmaceuticals LLC | $43.74 | 2022-2023 | Sotalol Hydrochloride |
| E.R. Squibb & Sons, L.L.C. | $38.86 | 2022-2023 | Camzyos |
| Biotronik INC. | $29.02 | 2021 | |
| Pfizer INC. | $24.59 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayna Ling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.